Essex Property Trust, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Essex Property Trust, Inc. trades at $282.04 (market cap $18.15B), while IDEXX Laboratories, Inc. trades at $572.59 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.5× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ESS | IDXX | |
|---|---|---|
Market Cap | $18.15B | $46.22B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $766.68 |
52-Week Low | $239.61 | $526.44 |
Enterprise Value | $24.75B | $47.12B |
Dividend Yield | 3.93% | — |
Signals from Pluang's Aura AI — not financial advice
ESS trades at $281.92, down 0.46% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year guidance, reflecting strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is projected to moderate in 2026. Recent news highlights institutional buying by Amundi and recognition as a top GreenTech company.
The outlook is mixed: raised guidance and solid fundamentals support upside toward the $305.86 consensus price target, but technical weakness and a high debt load pose near-term risks. Investor sentiment is cautiously optimistic, with 40% of analysts rating the stock a Buy, though the bearish technical picture suggests potential volatility ahead.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Trailing returns across standard periods
Latest headlines on both assets
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →